SCHEMBL3970865

SCHEMBL3970865

COC(=O)c1cc(I)c(N)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.54
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 6/20 0.50
GAA P10253 6/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 3/20 0.50
GLA P06280 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
NQO2 P16083 1/20 0.50
ABL1 P00519 1/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
POLB P06746 1/20 0.40
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
FLT1 P17948 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2690892 0.93 KDM4E (0.50) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL29790105 0.93 KDM4E (0.50) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL24413993 0.87 CFTR (0.58) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL12021191 0.86 CFTR (0.62) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL1720999 0.85 KDM4E (0.56) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL1920431 0.83 CFTR (0.46) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL274700 0.83 KDM4E (0.55) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL30280800 0.83 CFTR (0.46) CFTRKDM4EALDH1A1GAAHSD17B10
Hydrochloric Acid SCHEMBL5417457 0.81 KDM4E (0.53) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL2596444 0.81 GAA (0.66) CFTRKDM4EALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540238-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP disclosed
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-04-10 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
WO-2023244818-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
EP-4247789-A1 FUNGICIDAL ARYL AMIDINES Corteva Agriscience LLC (US) 2023-09-27 EP disclosed
CN-116529235-A Fungicidal aryl amidines 科迪华农业科技有限责任公司 2023-08-01 CN disclosed
US-20220220068-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2022-07-14 US disclosed
US-20220220068-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2022-07-14 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
EP-1545528-A4 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC (US) 2006-07-26 EP disclosed
EP-1545528-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC. (US) 2005-06-29 EP disclosed
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. 2004-07-22 US disclosed
WO-2004022712-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE SCIOS INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220068-A1 FUNGICIDAL ARYL AMIDINES CYP1A1, CYP1A2, CYP1B1 CFTR 303/4885KDM4E 648/4885ALDH1A1 105/4885
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase MAPK1, MAPKAPK2, MAPK4 CFTR 4773/4885KDM4E 1404/4885ALDH1A1 2371/4885
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE MAPK1, MAPKAPK2, MAPKAPK5 CFTR 4821/4885KDM4E 1711/4885ALDH1A1 1773/4885
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CYP1A1, CYP1A2, CYP1B1 CFTR 303/4885KDM4E 648/4885ALDH1A1 105/4885
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 CFTR 4669/4885KDM4E 394/4885ALDH1A1 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.